SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

OKLO is trending as investors debate its valuation and future prospects, particularly in relation to AI data centers. Community discussions revolve around whether the stock is overhyped, with some pointing to insider selling and a lack of current revenue, while bulls highlight potential government support and technological advancements in nuclear energy. The stock's parabolic rise and recent pullback have intensified the debate between bulls and bears.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

QURE is trending due to positive clinical trial data showing its Huntington's disease therapy significantly slowed disease progression, sparking optimism for a potential cure. The community is buzzing about the implications of the trial results, with some discussing the possibility of a buyout and others cautioning against potential dilution from a new offering. This surge in interest reflects the broader excitement around gene therapy and its potential to treat previously untreatable conditions.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending due to renewed interest in quantum computing, fueled by news of government contracts and potential technological breakthroughs; the community is weighing the long-term potential of quantum against short-term hype and valuation concerns. Discussions include comparisons to other quantum stocks and speculation about an upcoming correction or offering. Overall, the stock's rapid gains have ignited both excitement and skepticism among investors.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors discuss potential ticker suppression and speculation about unusual ticker behavior before earnings. The community is focused on the company's upcoming earnings report and long-term revenue streams solidifying. Some investors believe this suppression is temporary and anticipate a significant move following the earnings report.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is trending as investors await news on potential NASA contracts and discuss technical analysis, including trend lines and Elliott Wave patterns, to gauge potential buy spots. Community members are debating the stock's short-term bearish signals versus long-term bullish prospects, particularly in light of exclusive NASA contracts and the broader space sector's momentum. Discussions also involve the impact of potential news releases and upcoming launches on the stock's performance.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending amid speculation around a potential investment from Apple and closer collaboration between the two tech giants, fueling community excitement about Intel's turnaround. This follows news of Nvidia's investment and government support, with many seeing this as a strategic move to bolster domestic chip manufacturing and challenge TSMC's dominance.

Eason Technology Ltd. engages in the provision of loan facilities to micro, small and medium size enterprises, and sole proprietors. It also offers microfinance lending services. The company was founded by Qi Ming Xu and Kang Kai Zeng on June 24, 2010 and is headquartered in Wuhan, China.

Eason Technology Ltd. - ADR

Eason Technology Ltd ADR

DXF is trending due to renewed interest in low-float Chinese stocks, with traders highlighting its small float and potential for a significant price surge. The community is discussing the possibility of a squeeze, drawing comparisons to other low-float runners, and anticipating news that could act as a catalyst. Some traders point to the stock's history of volatility and past runs, while others await the filing of the 20-F.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is trending as investors react to news of increased AI spending and a potential partnership with Nvidia. The community is discussing the stock's recent surge and whether it can reach previous highs, with some eyeing $200 as the next target. Broader conversations include the AI race between the U.S. and China, with some considering BABA as a key player in the sector.

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.

Immuneering Corp - Ordinary Shares Class A

IMRX is trending following the announcement of extraordinary survival data in a Phase 2a trial for pancreatic cancer treatment, leading to a surge of community discussion. Bullish investors are particularly enthusiastic due to positive survival data and an existing collaboration with Lilly. However, a proposed public offering is tempering immediate gains as the community assesses its potential impact.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as traders weigh recent market pullbacks against potential upside catalysts. Community discussions focus on whether current dips represent buying opportunities or the start of a larger correction, with some pointing to specific levels to watch. Economic data releases and overall market sentiment are also key factors influencing the conversation around QQQ.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Immuneering Stock Rises 21.7% on Supply Agreement With LLY

IMRX jumps 21.7% after striking a supply deal with Eli Lilly to test atebimetinib with the latter's olomorasib in non-small cell lung cancer.

Immuneering Corporation (IMRX) on Monday announced a clinical supply agreement with Eli Lilly and Company (LLY) for the latter’s investigational cancer drug Olomorasib.Immuneering <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/08/25/3138395/0/en/Immuneering-Announces-Clinical-Supply-Agreement-with-Lilly-to-Evaluate-Atebimetinib-in-Combination-with-Olomorasib.html">said</a> that the company would test its lead product candidate Atebimetinib, in combination with Olomorasib, in a planned mid-stage clinical trial in patients with a type of non-small cell lung cancer (NSCLC) who have progressed on prior therapy.In February, Immuneering announced a similar clinical trial agreement with Regeneron Pharmaceuticals to evaluate Atebimetinib in combination with Libtayo in patients with advanced non-small cell lung cancer.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IMRX">IMRX stock</a> trended within ‘bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels. IMRX stock traded 15% higher at the time of writing.<figure class="image"><img style="aspect-ratio:623/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_25_at_12_21_56_PM_png_6149d7e374.webp" alt="IMRX's Sentiment Meter and Message Volume as of 12:25 p.m. ET on Aug. 25, 2025 | Source: Stocktwits" width="623" height="61"><figcaption>IMRX's Sentiment Meter and Message Volume as of 12:25 p.m. ET on Aug. 25, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user said that they will buy more on dips.<stembedurl>https://stocktwits.com/BiotechBonesaw/message/626436428</stembedurl>Another user praised the company saying it has excellent products and good management.<stembedurl>https://stocktwits.com/OptimistJP/message/626406127</stembedurl>Chief Medical Officer of Immuneering Igor Matushansky said that the combination of the company’s drug with Lilly’s has the potential for enhanced tumor regression, delayed emergence of tumor resistance, and prolonged survival relative to monotherapy.&nbsp;&nbsp;&nbsp;&nbsp;“This dual-targeted approach has the potential to improve outcomes in a population with limited effective treatment options,” Matushansky added. Immuneering further said that it will maintain global development and commercialization rights to its drug Atebimetinib.IMRX stock is up by 156% this year and by about 381% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-exec-hints-at-possible-price-hike-on-model-y-in-us/chsssVVRdSR">Tesla Executive Hints At Possible Price Hike On Model Y In US: Retail Highlights Negative Catalysts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

Immuneering Inks Supply Agreement With Eli Lilly For Latter’s Investigational Cancer Therapy: Retail Looks To Buy The Stock On Dips

Immuneering said that the company would test its lead product candidate Atebimetinib, in combination with Olomorasib, in a planned mid-stage clinical trial in patients with a type of non-small cell lung cancer who have progressed on prior therapy.

Equity

Shares&nbsp;of Immuneering Corp saw increased retail chatter on Tuesday after the company reported positive interim results from its Phase 2a trial of atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer.The stock&nbsp;initially surged on the news during morning trade&nbsp;but closed down 23.2% at $1.82 on Tuesday and slipped another 2.2% to $1.78 in after-hours trading.Trading activity likely indicated profit-taking, as Immuneering’s stock has gained more than 25% over the past month.The data demonstrated an overall survival (OS) rate of 94% and a progression-free survival (PFS) rate of 72% at 6 months among 34 patients who received atebimetinib at 320 mg once daily plus modified mGnP.&nbsp;Median OS and PFS had not yet been reached.&nbsp;The benchmark 6-month OS and PFS rates for&nbsp;the current standard-of-care treatment in this population are 67% and 44%, respectively.The overall response rate stood at 39%, with disease control seen in 81% of patients.&nbsp;Investigators noted durable tumor regressions, with multiple lesions reportedly rendered undetectable.&nbsp;No Grade 3 or higher adverse events were observed across most categories typically linked to standard chemotherapy regimens.The data prompted Immuneering to increase the trial’s target enrollment to 50 patients.&nbsp;A pivotal, randomized trial is planned for 2026, pending regulatory feedback later this year.Immuneering said additional Phase 2a data and regulatory milestones are expected in Q4 2025.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.One user noted that the stock has never undergone a reverse split and suggested it has multiple upside targets, even speculating on potential buyout interest.&nbsp;<stembedurl>https://stocktwits.com/sam92/message/618211510</stembedurl>Another long-time holder said belief in the stock remains strong.<stembedurl>https://stocktwits.com/Starkravingmad/message/618210680</stembedurl>The stock has declined 17.7% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Illustration depicting tumour infiltrating lymphocyte (TIL) therapy for cancer treatment. During TIL therapy, T-cells (blue) that recognise tumour cells (red) are obtained from a patient. | Image source: Getty Images

Immuneering’s Positive Pancreatic Cancer Trial Data Sparks Bullish Retail Sentiment Even As Profit-Taking Cools Rally

The company plans to launch a pivotal trial in 2026 and expects additional clinical data and regulatory feedback by the end of 2025. 

U.S. biotech stocks, particularly small and mid-cap companies, remained a focal point for retail investors in 2024 despite significant volatility.&nbsp;Collectively, biotech stocks on U.S. bourses have garnered over 3.3 million watchers on Stocktwits.&nbsp;Here are the top five biotech stocks that saw the most significant surge in new followers this year:CERo Therapeutics Holdings Inc. (CERO): +44544% WatchersThis immunotherapy company develops engineered T-cell therapeutics for cancer. <a href="https://stocktwits.com/symbol/CERO">CERO</a> saw major retail interest following the FDA’s clearance of its lead compound, CER-1236, for Phase 1 clinical trials after an earlier clinical hold. The company went public via a SPAC merger in February and has lost 99% of its value this year.Psyence Biomedical Ltd. (PBM): +6741% WatchersKnown for developing natural psilocybin products for treating psychological trauma, PBM gained attention for positive results from its Phase IIb trial in adjustment disorder treatment for terminal cancer patients.&nbsp;Its&nbsp;shares have also dropped 99% this year since the company’s March SPAC debut.Azitra Inc. (AZTR): +2365% WatchersSpecializing in dermatological therapies using engineered proteins and live biotherapeutic products, AZTR drew attention for securing&nbsp;a fast track designation for ATR-04 and other multiple&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-are-azitra-shares-trending-on-wednesday/c7r4UW0RbE">patents</a>. Its stock value has plunged more than 99% since its debut in June last year.Immuneering Corporation (IMRX): +2248% WatchersFocused on oncology, IMRX’s lead program, IMM-1-104, received FDA orphan drug designation for pancreatic cancer and fast-track status to treat certain melanoma patients, and is currently in a Phase 2a trial. <a href="https://stocktwits.com/symbol/IMRX">IMRX shares</a> have declined over 70% year-to-date.NKGen Biotech Inc. (NKGN): +1260% WatchersNKGN develops autologous and CAR-NK cell therapies. Its SNK01 natural killer cell therapy for Alzheimer’s disease showed promising results, with 90% of patients maintaining or improving cognitive function. The candidate was cleared to progress into phase 2 clinical development, which will involve a larger group of 30 patients with moderate Alzheimer's disease. Shares, however, have fallen more than 66% this year.Despite their stock price struggles, these companies have captivated retail investors with groundbreaking therapies and promising clinical developments, positioning them as key biotech names to watch heading into 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

Top 5 Biotech Stocks That Captured Retail Investor Interest The Most In 2024

Despite their stock price struggles, these companies have captivated retail investors with groundbreaking therapies and promising clinical developments.

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options PR Newswire VANCOUVER, BC, Dec. 23, 2024 Issued on...

Why Is Nanocap Immuneering Stock Trading Higher On Friday?

Immuneering reported promising initial response data from its Phase 2a trial for IMM-1-104 combined with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer, showing a 40% response...

Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatment

Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatment Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatment PR Newswire...

Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference

CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for...

Immuneering price target lowered by $12 at Mizuho, here's why

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Buy Rating Affirmed for Immuneering on Solid Trial Progress and Insider Confidence

Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Immuneering (IMRX Research Report) on March 27 and set a price target of...

Will Costco Wholesale ($COST) beat its quarterly EPS estimate? 
 
*Powered by Polymarket

Stocktwits

Costco Wholesale Corp

) beat its quarterly EPS estimate? 
 
*Powered by Polymarket

Current Price	$13.09
Prev Close	$8.59
Open	$8.64
Dividend Yield	0.00%
50-Day Moving Average	$5.14
Beta	1.16
Avg. Volume	844,106.05
PE Ratio	-4.53

52-Week High	$10.08
52-Week Low	$1.10
Market Capitalization	$357.09M
EPS (Annual)	-$2.04
Price to Book	10.68
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

IMRX
Immuneering Corp - Ordinary Shares Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IMRX News

IMRX Immuneering Corp - Ordinary Shares Class A